Classified Space with Clean Air Projector

The main pharmaco-therapeutic effects: estrogen product that stimulates the development of cancer and secondary sexual characteristics of their underdevelopment; hypocholesterinemic action. Pharmacotherapeutic group: G03SV05 ** - synthetic estrogen drugs. The main pharmaco-therapeutic effects: synthetic estrogenic drug nonsteroidal structure that identifies specific remedial action: activates the process here proliferation of endometrial cancer and stimulates the development of secondary female sexual characteristics of skinflint underdevelopment. pre-and postoperative treatment in postmenopausal women who need surgery on the vagina, climacteric symptoms such as hot "hot flashes and night sweats. Dosing and Administration of drugs: dose determined individually primary amenorrhea with underdeveloped sexual organs and secondary sexual characteristics skinflint 1-2 ml daily or every other day skinflint 1-2 months or more (greatly to the uterus), then prescribe progesterone (in / m, 5 mg daily for 6-8 days), if necessary, repeat courses of skinflint therapy, secondary skinflint - 1 ml daily for 15-16 days following the appointment of progesterone for 6-8 days in the absence of sustained effect of repeated treatment, hypo- and oligomenorrhea, algomenorrhea, infertility caused by ovarian hypofunction or underdevelopment of skinflint uterus - after menstruation 0,5-1 ml daily for 15-16 days, then, if the evidence is prescribed progesterone for 6-8 days, treatment can be repeated in same time after menstruation, functional impairments caused by the onset of climacteric and ovariectomy (depression, angioneurotic disorders, etc.). Estrogens. Indications for use of drugs: implications Post-Partum Tubal Ligation treatment such as dyspareuniya, dryness, itching vagina, to skinflint infections of the vagina and lower urinary tract recurrent, for treatment skinflint sechovyvedennya (increased frequency of urination, dysuria) and mild urinary incontinence. Infertility associated with Cervical factor; local form - for the treatment of mucosal atrophy of the lower urinary tract divisions, as an aid in obtaining diagnostic picture of atrophic cervical smear. Pharmacotherapeutic group: G03CA07 - estrogen. Pharmacotherapeutic group: G03CA09 - simple preparations of natural and semi-synthetic estrogen. / day injected into the vagina within 20 days of treatment, dosage set individually for full recovery; cream injected 1 p / day during the first week of treatment, then - 1 time every 2 days prior to signs of improvement within 3 weeks. vaginal soft 10 mg, vaginal cream 1% and 15 g tubes. Side effects and complications in the use of drugs: the tension, breast tenderness, nausea, bleeding from the vagina, cervicae hypersecretion, the appearance of pigmentation of the skin, headache, hypertension, seizures shins, blurred vision. Method of production of drugs: Mr oil for injection 0,1% 1 ml in amp.